Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H28O4 |
| Molecular Weight | 344.4446 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]3([H])[C@@]2([H])C(=O)C=C4C[C@H](CC[C@]34C)OC(C)=O
InChI
InChIKey=VVSMJVQHDZUPIL-XFKPDKBWSA-N
InChI=1S/C21H28O4/c1-12(22)25-14-6-8-20(2)13(10-14)11-17(23)19-15-4-5-18(24)21(15,3)9-7-16(19)20/h11,14-16,19H,4-10H2,1-3H3/t14-,15-,16-,19-,20-,21-/m0/s1
| Molecular Formula | C21H28O4 |
| Molecular Weight | 344.4446 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| [Effects of 7-oxo-DHEA treatment on the immunoreactivity of BALB/c mice subjected to chronic mild stress]. | 2003 Dec |
|
| Steroids and thermogenesis. | 2006 |
|
| How short-term transdermal treatment of men with 7-oxo-dehydroepiandrosterone influence thyroid function. | 2006 |
|
| A novel radioimmunoassay of 7-oxo-DHEA and its physiological levels. | 2007 Apr |
|
| Dehydroepiandrosterone 7alpha-hydroxylation in human tissues: possible interference with type 1 11beta-hydroxysteroid dehydrogenase-mediated processes. | 2007 May |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:28:56 GMT 2023
by
admin
on
Sat Dec 16 08:28:56 GMT 2023
|
| Record UNII |
84RQ0XOM11
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
84RQ0XOM11
Created by
admin on Sat Dec 16 08:28:56 GMT 2023 , Edited by admin on Sat Dec 16 08:28:56 GMT 2023
|
PRIMARY | |||
|
1747869
Created by
admin on Sat Dec 16 08:28:56 GMT 2023 , Edited by admin on Sat Dec 16 08:28:56 GMT 2023
|
PRIMARY | |||
|
84RQ0XOM11
Created by
admin on Sat Dec 16 08:28:56 GMT 2023 , Edited by admin on Sat Dec 16 08:28:56 GMT 2023
|
PRIMARY | |||
|
300000033938
Created by
admin on Sat Dec 16 08:28:56 GMT 2023 , Edited by admin on Sat Dec 16 08:28:56 GMT 2023
|
PRIMARY | |||
|
1449-61-2
Created by
admin on Sat Dec 16 08:28:56 GMT 2023 , Edited by admin on Sat Dec 16 08:28:56 GMT 2023
|
PRIMARY | |||
|
9798229
Created by
admin on Sat Dec 16 08:28:56 GMT 2023 , Edited by admin on Sat Dec 16 08:28:56 GMT 2023
|
PRIMARY | |||
|
DTXSID70932445
Created by
admin on Sat Dec 16 08:28:56 GMT 2023 , Edited by admin on Sat Dec 16 08:28:56 GMT 2023
|
PRIMARY | |||
|
134911
Created by
admin on Sat Dec 16 08:28:56 GMT 2023 , Edited by admin on Sat Dec 16 08:28:56 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE -> PARENT |
Plasma concentrations 12 hours after the 3.beta.-acetyl-7-oxo-DHEA dose at 7 and 28 days on the 200 mg/d dose were 15.8 and 16.3 mcg/L respectively (n=16).
IN-VIVO
PLASMA
|
||
|
METABOLITE ACTIVE -> PRODRUG |
